Next 10 |
2024-07-02 10:45:05 ET Ford Motor Co. (F) F is trading UP for the last 5 days, and it at trading at $12.82 with volume of 15,047,573 and a one day change of $0.06 (0.47%). Ford Motor Co. has a 52-week low of 9.63 and a 52-week high of $15.42. The business's 50-day moving average pri...
2024-07-01 14:00:07 ET Josh Schimmer from Cantor Fitzgerald issued a price target of $90.00 for LBPH on 2024-07-01 12:46:00. The adjusted price target was set to $90.00. At the time of the announcement, LBPH was trading at $28.76. The overall price target consensus is at...
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical...
Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3% Favorable safety and tolerability results observed ...
2024-05-26 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-20 16:47:47 ET Gainers: Maravai LifeSciences ( MRVI ) +5% . Caribou Biosciences ( CRBU ) +4% . Greenidge Generation Holdings ( GREE ) +4% . Cipher Mining ( CIFR ) +4% . SIGA Technologies ( SIGA ) +4%...
2024-05-03 14:53:23 ET More on Longboard Pharmaceuticals Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely Longboard stock up 8% as Citi initiates at buy, citing takeover potential Seeking Alpha’s Quant Rating on Longboard ...
Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) were reported in Q1 2024 Presented late-breaking data for bexicaserin from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeti...
2024-04-30 18:00:03 ET Joel Beatty from Robert W. Baird issued a price target of $36.00 for LBPH on 2024-04-30 16:11:00. The adjusted price target was set to $36.00. At the time of the announcement, LBPH was trading at $21.3. The overall price target consensus is at $16....
2024-04-16 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Longboard Pharmaceuticals Inc. Company Name:
LBPH Stock Symbol:
NASDAQ Market:
Longboard Pharmaceuticals Inc. Website:
2024-07-02 10:45:05 ET Ford Motor Co. (F) F is trading UP for the last 5 days, and it at trading at $12.82 with volume of 15,047,573 and a one day change of $0.06 (0.47%). Ford Motor Co. has a 52-week low of 9.63 and a 52-week high of $15.42. The business's 50-day moving average pri...
2024-07-01 14:00:07 ET Josh Schimmer from Cantor Fitzgerald issued a price target of $90.00 for LBPH on 2024-07-01 12:46:00. The adjusted price target was set to $90.00. At the time of the announcement, LBPH was trading at $28.76. The overall price target consensus is at...
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical...